Cretostimogene grenadenorepvec (CG0070) clinical studies
Our lead candidate, cretostimogene grenadenorepvec (CG0070), is a targeted oncolytic intravesically delivered immunotherapy agent that is currently in a Phase 3 trial for the treatment of BCG-unresponsive NMIBC. It is also in Phase 2 study in combination with KEYTRUDA® A (pembrolizumab) in the same indication. Other types of bladder cancer are being evaluated with cretostimogene in combination with OPDIVO® B (nivolumab). We are planning other studies in bladder cancer.
Cretostimogene (CG0070)
High-Risk, BCG-Unresponsive NMIBC (BOND-003)
Cretostimogene + KEYTRUDA®
High-Risk, BCG-Unresponsive NMIBC (CORE-001)
Cretostimogene + OPDIVO®
High-Risk, Cisplatin Ineligible MIBC (CORE-002)
Cretostimogene (CG0070)
Intermediate-Risk, BCG-Naive NMIBC (PIVOT-006)
Cretostimogene (CG0070)
High-Risk, BCG-Naive & BCG-exposed NMIBC (CORE-008)
Current Program
Planned Studies
Well Positioned to Tackle Different Stages of Bladder Cancer
Other studies are planned in the near future
A KEYTRUDA is a registered trademark of Merck Sharp and Dohme.
B OPDIVO is a registered trademark of Bristol-Myers Squibb Company.
